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Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease characterized by joint and extra-articular involvement.
Among them, interstitial lung disease (ILD) is one of the most common and severe extra-articular manifestations, with a negative
impact on both therapeutic approach and overall prognosis. ILD can occur at any point of the natural history of RA, sometimes
before the appearance of joint involvement. Since no controlled studies are available, the therapeutic approach to RA-ILD is still
debated and based on empirical approaches dependent on retrospective studies and case series. Here, we report the case of a 75-
year-old patient affected by RA complicated by ILD successfully treated with a combination therapy of an antifibrotic agent,
nintedanib, and an inhibitor of IL-6 receptor, sarilumab. We obtained a sustained remission of the joint involvement and,
simultaneously, a stabilization of the respiratory symptoms and function, with a good safety profile. To date, this is the first report
describing a combination therapy with nintedanib and a disease-modifying antirheumatic drug (DMARD) for the management of
RA complicated by ILD. Future prospective studies are needed to better define efficacy and safety of this approach in the treatment
of these subjects.
1. Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, inflam-
matory disease affecting 0.5–1% of the population world-
wide. It is characterized by chronic, symmetrical, erosive
synovitis and sometimes by extra-articular manifestations
[1]. Among them, lung involvement is common and in-
cludes a wide spectrum of disorders ranging from airways
and pleural disease, bronchiectasis and nodules, to infection
and drug toxicity [1].
Interstitial lung disease (ILD) is the most common lung
involvement, with an estimated prevalence ranging from 4 to
30%, and significantly affects the therapeutic approach,
quality of life, morbidity, and mortality of RA patients [2, 3].
+e treatment of RA-ILD is still debated, and it is mainly
based on corticosteroids and immunosuppressants [4].
Usual interstitial pneumonia is the more frequent ILD
pattern observed in RA, followed by nonspecific interstitial
pneumonia (more typical of connective tissue disease, CTD).
Although RA-UIP is frequently reported to have a better
prognosis than idiopathic pulmonary fibrosis (IPF), its role
on the prognosis of RA-patients is not yet well defined [5].
Nintedanib is a small molecule triple tyrosine-kinase
inhibitor approved as an antifibrotic agent for the treatment
of IPF [6]. Nintedanib has shown a significant efficacy in
reducing the annual rate of decline of forced vital capacity
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(FVC) in subjects with IPF in comparison with placebo [6]
and very recently showed efficacy also in the treatment of
fibrosing ILD different by IPF [7].
Here, we present the case of a patient with RA-ILD
treated with nintedanib in association with a biologic an-
tirheumatic drug.
2. Case Report
A 75-year-old man, former smoker (40 pack-years, until
2007), was referred to the Respiratory Unit of our university
hospital because of the appearance of a persistent and
productive cough associated with worsening dyspnea on
exertion in November 2016. His past clinical history revealed
the presence of ischemic heart disease treated with triple
percutaneous transluminal coronary angioplasty, type 2
diabetes mellitus, systemic arterial hypertension, and benign
prostatic hyperplasia.
He underwent high-resolution computer tomography
(HRCT) with the detection of reticular ILD characterized by
bibasal thickening of the interstice and interlobular septa
associated with traction bronchiectasis.
At the time of diagnosis, FVC was normal (FVC 109%),
while the diffusion capacity for carbon monoxide test
(DLCO) was severely reduced (DLCO Sb 35%). Echocar-
diography was not suggestive for pulmonary arterial hy-
pertension. +e patient showed digital clubbing at physical
examination and chest auscultation revealed velcro crackles.
For the detection of low-titer anti-citrullinated peptides
antibodies (ACPA) (89UI/mm), he was referred to our
Rheumatology Unit. +e patient did not complain arthritis,
sicca syndrome, Raynaud phenomenon, or other symptoms,
or sign related to inflammatory arthritis, or CTDs. Both
Schirmer test and nailfold capillaroscopy were negative.
Erythrocyte sedimentation rate (ESR), C-reactive protein
(CRP), antinuclear antibodies (ANA) including extractable
nuclear antigen (ENA), and anti-granulocyte antibodies
(ANCA), and rheumatoid factor (RF) were all negative.
A surgical lung biopsy confirmed the presence of a UIP
pattern, showing an altered architecture due to “honey-
combing” aspects accompanied by mild to moderate chronic
interstitial inflammation. A diagnosis of IPF was performed,
and the patient began a treatment with nintedanib (150mg
twice daily), which was well tolerated.
In December 2017, he was newly referred to our
Rheumatology Unit for the appearance of inflammatory
arthralgias involving small joints of the hands and swelling
of the left wrist associated with an increase in ESR and CRP
(30mm/h and 24mg/l, respectively) and the presence of
rheumatoid factor (174 IU/ml) besides ACPA. +e disease
activity score in 28 joints (DAS-28-CRP) was 3.96 (moderate
disease activity). Ultrasound confirmed the presence of
bilateral arthritis of the wrists with power-Doppler posi-
tivity. A diagnosis of RA was performed according to 2010
ACR/EULAR criteria [8], and we started a low-dose steroid
therapy (methylprednisolone 4mg/daily) and hydrox-
ycloroquine (200mg twice daily), in association with nin-
tedanib, was decreased to 100mg twice daily because of the
appearance of drug-related diarrhea.
In February 2019, an arthritis relapse occurred involving
small joints of the hands and the knees. ESR and CRP
(36mm/h and 21mg/l, respectively) increased again (DAS
28 6.71).
A suspected progression of lung fibrosis at HRCT was
also observed, with an increase of fibrosis in the midbasal
and in the subpleural and periscissural areas, and an increase
in traction bronchiectasis and honeycombing aspects, even if
symptoms and respiratory function remained stable (Fig-
ure 1). X-rays of the hands showed typical bone erosions in
several metacarpophalangeal joints.
In April 2019, indeed, we proposed the association with
anti-IL6 receptor antagonist sarilumab (200mg every two
week) achieving a regression of articular involvement
(DAS 28-PCR 2.31 one month after), that persisted for 6
months.
3. Discussion
ILD has a significant impact on morbidity and mortality and
represents a current challenge in the therapeutic approach to
RA. Treatment, mainly based on corticosteroids and im-
munosuppressants [4], is not well defined and efficacy data
are not still available. On the other hand, the supposed role
of many conventional and biologic disease-modifying an-
tirheumatic drugs (DMARDs) in the onset or worsening of
preexisting ILD in RA further complicates the therapeutic
choice for these patients [3, 9, 10].
Nintedanib is an antifibrotic agent approved for the
treatment of IPF, and recently its efficacy has been dem-
onstrated also in secondary forms of fibrosing ILD [6, 7]. It
inhibits the signal transmission at vascular endothelial
growth factor receptors, platelet-derived growth factor re-
ceptors, and fibroblast growth factor receptors associated
with proliferation, migration, and transformation of fibro-
blasts [6].
+ere is an increasing interest about the possible role of
nintedanib in the treatment of progressive ILD other than
IPF. Because of clinical and radiological similarity between
RA-ILD and IPF, it is expected that nintedanib could
produce similar effects in slowing the progression of the
disease. Preclinical data support a possible effect of ninte-
danib in fundamental processes of lung fibrosis, and that the
antifibrotic activity is independent of the cause of the
fibrosing lung disease [11–14]. Furthermore, the frequent
association between UIP and RA allows us to speculate that
nintedanib might also have efficacy in RA-ILD [15, 16].
A randomized, double-blind, placebo-controlled, phase
III trial (INBUILD trial) recently assessed the efficacy and
safety of nintedanib (150mg twice daily) versus placebo in
663 patients with a diagnosis of ILD other than IPF, in-
cluding subjects affected by RA [17]. Patients eligible for the
study presented features of diffuse fibrosing lung disease
affecting more than 10% of lung volume on HRCT;
moreover, they showed disease progression in the last two
years before screening, according to FVC, respiratory
symptoms, or HRCT. In particular, the study population
included a subgroup of patients with UIP-like pattern,
namely, patients with reticular abnormalities and traction
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bronchiectasis with or without honeycombing on HRCT
(412 patients, 62.1%) [7].
+e patients who received nintedanib showed a slower
progression of ILD compared to placebo, as shown by lower
decline in the annual rate of FVC over the 52-week period,
both in overall population and in UIP-like fibrotic patterns
group. Interestingly, the absolute treatment effect of nin-
tedanib in this study was similar in magnitude to those
observed in pooled data from the INPULSIS trial [7].
To our knowledge, this is the second report of a patient
with RA-ILD treated with nintedanib, and for the first time,
we describe the association between nintedanib and a bio-
logic DMARD.
Kakuwa et al. described, for the first time, a 74-year-old
man presenting the UIP pattern at HRCT who was diag-
nosed with IPF and subsequently developed an inflamma-
tory articular involvement typical of RA, with positivity of
ACPA and RF. +e patient was successfully treated with
nintedanib [18].
In our patient, treatment with nintedanib allowed
maintenance of lung function along the follow-up period,
despite that HRCT showed a progression of fibrotic fea-
tures of disease. On the other side, we obtained the re-
mission of the joint involvement, observing a good safety
profile of the combination therapy, without observing any
other side effects. Finally, we need data from specific
controlled trials to evaluate the safety and effectiveness of
nintedanib in RA-related ILD [7, 18] and the possible
association with conventional, biological, and targeted-
synthetic DMARDs.
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Figure 1: Clinical case summary. HRCT: high-resolution computer tomography; ILD: interstitial lung disease; RA: rheumatoid arthritis;
FVC: forced vital capacity; DLCO: diffusing capacity for carbon monoxide test; CRP: c-reactive protein; ACPA: anti-citrullinated peptides
antibodies; RF: rheumatoid factor; DAS 28-PCR: disease activity score on 28 joints.
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